ACU Stock Surges on Q2 2026 EPS Beat and MyMedic Margin Expansion

• Acme United reported Q2 2026 EPS of $1.22, beating estimates by 50.62% amid a 16% YoY sales increase driven by the MyMedic acquisition.
• Gross margins expanded to 42.6% as lower-cost inventory replaced higher-tariff stock, though elevated SG&A and tariff risks persist as key headwinds.
• Six Wall Street analysts maintain a Strong Buy consensus with a $64.26 mean price target, projecting 16.36% revenue growth for the full year 2026.

Acme United Corporation delivered exceptional second-quarter 2026 financial results that significantly surpassed market expectations. Earnings per share reached $1.22, eclipsing the consensus estimate of $0.81 and representing a 50.62% positive surprise. This performance was accompanied by revenue of $62.7 million, which exceeded the forecast of $58.1 million by nearly 8%. The market responded decisively to these figures, with the stock price surging between 11.9% and 17.5% immediately following the report.

What Drives the Strong Q2 2026 Financial Performance?

The primary catalyst for this financial outperformance was the strategic acquisition of MyMedic, a supplier of tactical and trauma products. Sales increased by 16% year-over-year, with the acquisition accounting for a significant portion of this growth. When excluding the impact of the MyMedic acquisition, underlying organic growth stood at a solid 8%, indicating robust demand across the company's traditional segments.

A critical component of this success was the expansion of gross margins to 42.6%, up from 41.0% in the prior year period. Management attributes this margin improvement to favorable product mix and operational efficiencies gained through the integration of MyMedic into the first aid and medical segments. The company continues to balance its traditional cutting and measuring tools with these higher-growth medical offerings, which provide recurring revenue potential.

How Is Management Navigating Tariff Pressures and Cost Risks?

Looking ahead, Acme United anticipates continued margin recovery as the company strategically manages tariff pressures. CEO Walter Johnsen indicated that the firm is allowing lower-cost inventory to replace higher-tariff stock throughout the remainder of 2026. This inventory cycle is expected to further alleviate cost pressures and support profitability as the year progresses. The company also expects strong fourth-quarter profitability driven by seasonal demand, particularly in the first aid and safety segment.

Despite the positive outlook, several financial headwinds remain. Selling, general, and administrative expenses (SG&A) remain elevated at 32% of sales, which continues to weigh on net income. In the first quarter of 2026, net income had already fallen by 40% despite sales growth, highlighting the sensitivity of margins to operating costs. Additional risks include ongoing tariff fluctuations, freight cost volatility, and currency risks, particularly in the Canadian market which has lagged behind other regions.

What Do Analysts Project for Acme United's Future Growth?

Wall Street maintains a Strong Buy consensus for Acme United, with six analysts covering the stock. The mean price target stands at $64.26, implying a modest 4.74% upside from the current trading price of $61.35. This consensus has seen upward revisions, with the average price target increasing by 26% over the past three months. Analysts project full-year 2026 revenue to reach $228.7 million, representing 16.36% year-over-year growth.

For the upcoming third quarter, expected on October 19, 2026, analysts forecast an EPS of $0.69 and revenue of $56.95 million. Long-term forecasts suggest a three-year revenue compound annual growth rate (CAGR) of 7.43%, supported by a strategic goal to reach $300 million in revenue within three years. To support these growth initiatives and operational needs, the company recently secured a new $65 million syndicated credit facility with HSBC. However, some estimates indicate potential margin compression in 2027 and 2028 as operating costs may continue to impact EBIT margins.